Patients continue to see the benefits of transcatheter mitral valve replacement a full two years after treatment.

Considering the study's high-risk patient population, researchers were especially impressed by these one-year outcomes.

The team behind the new pilot study said additional research is still necessary to confirm its findings. 

While the manufacturer says its solution is a safe and effective treatment option, the FDA wanted more information. 

Overall, mitral valve surgery after TEER was associated with a 30-day mortality rate of 16.6% and one-year mortality rate of 31.3%.

MVP also appears to increase the risk of certain problems during childbirth. 

Researchers turned to recent Medicare data to learn more about ongoing trends in interventional cardiology. 

Early counseling should be stressed for women with congenital heart defects, according to the analysis.